Market Summary
USD98.05+1.01
Market Closed1.04%
ABT Stock Price
ABT RSI Chart
ABT Valuation
ABT Price/Sales (Trailing)
ABT Profitability
ABT Fundamentals
ABT Revenue
ABT Earnings
Price Action
52 Week Range
93.25123.22
(Low)(High)
Last 7 days
-1.0%
Last 30 days
-4.5%
Last 90 days
-9.4%
Trailing 12 Months
-15.7%
ABT Financial Health
ABT Investor Care
Peers (Alternatives to Abbott Laboratories)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
DHR | 180.7B | 31.5B | -0.78% | -13.30% | 25.07 | 5.74 | 6.85% | 12.06% |
ABT | 171.9B | 43.7B | -4.52% | -15.68% | 24.79 | 3.94 | 1.34% | -1.95% |
MDT | 105.6B | 30.8B | -6.73% | -24.80% | 25.98 | 3.43 | -3.19% | -17.38% |
ISRG | 89.7B | 6.2B | 9.79% | -8.77% | 67.87 | 14.42 | 8.97% | -22.43% |
IDXX | 40.2B | 3.4B | 1.94% | -10.16% | 59.26 | 11.95 | 4.73% | -8.83% |
| MID-CAP | ||||||||
PEN | 10.5B | 847.1M | 5.10% | 33.54% | -5.2K | 12.36 | 13.32% | -137.89% |
NEOG | 3.9B | 630.7M | -5.79% | -41.33% | -242.52 | 6.24 | 25.40% | -128.45% |
QDEL | 3.7B | - | -3.05% | -21.16% | 3.27 | 1.42 | - | - |
| SMALL-CAP | ||||||||
CYRX | 1.1B | 237.3M | 15.32% | -32.47% | -24.23 | 4.63 | 6.59% | 84.02% |
HSKA | 958.4M | 257.3M | 13.67% | -32.65% | -48.19 | 3.72 | 1.41% | -1632.49% |
APEN | 412.1M | 71.7M | -0.40% | 60.36% | -10.13 | 5.75 | 20.17% | -128.83% |
SRDX | 260.1M | 101.9M | -22.22% | -55.97% | -8.05 | 2.55 | -3.74% | -420.65% |
DARE | 85.6M | - | -4.67% | -35.44% | -3.49 | 801.64 | 4.35% | 34.71% |
XTNT | 75.1M | 58.0M | -14.05% | 3.76% | -8.85 | 1.3 | 4.90% | -74.98% |
ZSAN | 2.7M | - | -66.21% | -40.16% | -0.05 | 4.15 | - | - |
Financials for Abbott Laboratories
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | -3.1% | 43,653 | 45,030 | 45,548 | 44,514 | 43,075 |
| S&GA Expenses | -0.7% | 11,248 | 11,323 | 11,359 | 11,328 | 11,324 |
| R&D Expenses | -1.3% | 2,888 | 2,925 | 2,815 | 2,785 | 2,742 |
| Costs and Expenses | -0.9% | 35,291 | 35,594 | 35,336 | 35,286 | 34,650 |
| EBITDA | -9.3% | 10,118 | 11,160 | 11,897 | 10,950 | - |
| EBITDA Margin | -6.5% | 0.23* | 0.25* | 0.26* | 0.25* | - |
| Earnings Before Taxes | -10.8% | 8,306 | 9,313 | 10,048 | 9,044 | 8,211 |
| EBT Margin | -8.0% | 0.19* | 0.21* | 0.22* | 0.20* | - |
| Interest Expenses | 4.3% | 558 | 535 | 527 | 529 | 533 |
| Net Income | -12.1% | 6,933 | 7,889 | 8,554 | 7,725 | 7,071 |
| Net Income Margin | -9.3% | 0.16* | 0.18* | 0.19* | 0.17* | - |
| Free Cahsflow | -8.6% | 7,804 | 8,541 | 8,468 | 8,152 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 2.2% | 74,438 | 72,801 | 74,202 | 74,007 | 75,196 |
| Current Assets | 1.5% | 25,224 | 24,845 | 24,956 | 23,429 | 24,239 |
| Cash Equivalents | 3.0% | 9,882 | 9,594 | 8,937 | 7,675 | 9,799 |
| Inventory | 7.7% | 6,173 | 5,734 | 5,899 | 5,691 | 5,157 |
| Net PPE | 5.4% | 9,162 | 8,689 | 8,818 | 8,908 | 8,959 |
| Goodwill | 2.3% | 22,799 | 22,284 | 22,744 | 23,179 | 23,231 |
| Current Liabilities | 15.9% | 15,489 | 13,365 | 12,392 | 12,647 | 13,105 |
| . Short Term Borrowings | - | - | - | - | - | - |
| Long Term Debt | - | 18,050 | - | - | - | - |
| LT Debt, Current | 101.5% | 2,251 | 1,117 | 5.00 | 4.00 | 754 |
| LT Debt, Non Current | -5.1% | 14,522 | 15,297 | 16,755 | 17,086 | 17,296 |
| Shareholder's Equity | 2.8% | 36,686 | 35,675 | 36,490 | 35,399 | 35,802 |
| Retained Earnings | 0.4% | 35,257 | 35,115 | 34,487 | 33,295 | 31,528 |
| Accumulated Depreciation | 4.1% | 11,050 | 10,617 | 10,640 | 10,613 | 10,405 |
| Shares Outstanding | -0.1% | 1,753 | 1,754 | 1,762 | - | - |
| Minority Interest | 4.8% | 219 | 209 | 226 | 230 | 222 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | -7.2% | 9,581 | 10,322 | 10,243 | 9,961 | 10,533 |
| Share Based Compensation | 1.3% | 685 | 676 | 667 | 657 | 640 |
| Cashflow From Investing | 2.2% | -1,740 | -1,779 | -1,946 | -1,946 | -2,008 |
| Cashflow From Financing | 5.3% | -7,636 | -8,065 | -7,899 | -8,350 | -5,494 |
| Dividend Payments | 0.8% | 3,309 | 3,284 | 3,259 | 3,234 | 3,202 |
| Buy Backs | -7.1% | 3,795 | 4,084 | 3,865 | 4,331 | 2,299 |
Risks for ABT
What is the probability of a big loss on ABT?
36.1%
Probability that Abbott Laboratories stock will be more than 20% underwater in next one year
5%
Probability that Abbott Laboratories stock will be more than 30% underwater in next one year.
0%
Probability that Abbott Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does ABT drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Abbott Laboratories was unfortunately bought at previous high price.
Drawdowns
Returns for ABT
Cumulative Returns on ABT
13.1%
10-Year Cumulative Returns
15.4%
7-Year Cumulative Returns
12.2%
5-Year Cumulative Returns
13.7%
3-Year Cumulative Returns
What are the long-term rolling returns for ABT?
FIve years rolling returns for Abbott Laboratories.
Annualized Returns
Which funds bought or sold ABT recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -2.48 | 626,133 | 6,465,130 | 0.18% |
2023-03-13 | Claro Advisors LLC | added | 35.55 | 158,798 | 589,798 | 0.19% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -3.34 | 7,272,550 | 82,384,600 | 0.09% |
2023-03-10 | MATHER GROUP, LLC. | added | 14.43 | 768,634 | 3,344,630 | 0.06% |
2023-03-08 | Pacific Wealth Management | reduced | -2.34 | 451,513 | 4,625,510 | 3.40% |
2023-03-08 | Capital Asset Advisory Services LLC | added | 21.93 | 458,625 | 1,619,620 | 0.13% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | reduced | -9.42 | 11,078 | 396,078 | 0.06% |
2023-03-07 | Great Lakes Retirement, Inc. | new | - | 1,099,960 | 1,099,960 | 0.28% |
2023-03-06 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | unchanged | - | 334,407 | 2,819,410 | 1.07% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | added | 0.87 | 3,623,700 | 28,696,700 | 1.78% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Abbott Laboratories News
Schedule 13G FIlings of Abbott Laboratories
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 8.92% | 155,480,794 | SC 13G/A | |
| Feb 06, 2023 | blackrock inc. | 8.0% | 139,526,216 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 8.43% | 149,152,264 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 7.8% | 137,155,602 | SC 13G/A | |
| Feb 16, 2021 | capital research global investors | 4.9% | 86,394,199 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 8.31% | 147,272,920 | SC 13G/A | |
| Jan 29, 2021 | blackrock inc. | 7.5% | 133,426,810 | SC 13G/A | |
| Feb 14, 2020 | capital research global investors | 6.4% | 113,689,293 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 8.58% | 151,783,436 | SC 13G/A | |
| Feb 05, 2020 | blackrock inc. | 7.1% | 124,728,602 | SC 13G/A |
ABT Fair Value
Abbott Laboratories fair value in different scenarios
The table shows the Fair Value estimates for Abbott Laboratories for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | - - | - - | - - | - - | - - |
| Current Inflation | 70.76 -27.83% | 90.64 -7.56% | 126.76 29.28% | 177.83 81.37% | 202.41 106.44% |
| Very High Inflation | - - | - - | - - | - - | - - |
Historical Abbott Laboratories Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Abbott Laboratories
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 17, 2023 | ARS | ARS | |
| Mar 17, 2023 | DEF 14A | DEF 14A | |
| Mar 17, 2023 | DEFA14A | DEFA14A | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading | |
| Mar 02, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for ABT
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-01 | Ahlberg Gregory A | sold | -132,622 | 100 | -1,317 | senior vice president |
2023-03-01 | Ginascol John F | sold | -94,960 | 100 | -943 | executive vice president |
2023-03-01 | DALE MICHAEL D | sold | -121,746 | 100 | -1,209 | senior vice president |
2023-03-01 | WOODGRIFT RANDEL WILLIAM | sold | -103,922 | 100 | -1,032 | senior vice president |
2023-03-01 | MANNING JOSEPH J | sold | -134,837 | 100 | -1,339 | executive vice president |
2023-03-01 | Salvadori Daniel Gesua Sive | sold | -109,260 | 100 | -1,085 | executive vice president |
2023-03-01 | Tyler Julie L. | sold | -52,867 | 100 | -525 | senior vice president |
2023-03-01 | Moreland Mary K | sold | -72,252 | 100 | -717 | executive vice president |
2023-03-01 | Funck, Jr. Robert E. | sold | -127,285 | 100 | -1,264 | executive vice president |
2023-03-01 | Earnhardt Lisa D | sold | -94,960 | 100 | -943 | executive vice president |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
ABT Income Statement
2022-12-31Consolidated Statement of Earnings - USD ($) shares in Millions, $ in Millions | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Income Statement [Abstract] | |||
| Net Sales | $ 43,653 | $ 43,075 | $ 34,608 |
| Cost of products sold, excluding amortization of intangible assets | 19,142 | 18,537 | 15,003 |
| Amortization of intangible assets | 2,013 | 2,047 | 2,132 |
| Research and development | 2,888 | 2,742 | 2,420 |
| Selling, general and administrative | 11,248 | 11,324 | 9,696 |
| Total Operating Cost and Expenses | 35,291 | 34,650 | 29,251 |
| Operating Earnings | 8,362 | 8,425 | 5,357 |
| Interest expense | 558 | 533 | 546 |
| Interest income | (183) | (43) | (46) |
| Net foreign exchange (gain) loss | 2 | 1 | (8) |
| Other (income) expense, net | (321) | (277) | (103) |
| Earnings from Continuing Operations Before Taxes | 8,306 | 8,211 | 4,968 |
| Taxes on Earnings from Continuing Operations | 1,373 | 1,140 | 497 |
| Earnings from Continuing Operations | 6,933 | 7,071 | 4,471 |
| Net Earnings from Discontinued Operations, net of taxes | 0 | 0 | 24 |
| Net Earnings | $ 6,933 | $ 7,071 | $ 4,495 |
| Basic Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | $ 3.94 | $ 3.97 | $ 2.51 |
| Discontinued Operations (in dollars per share) | 0 | 0 | 0.01 |
| Net Earnings (in dollars per share) | 3.94 | 3.97 | 2.52 |
| Diluted Earnings Per Common Share -- | |||
| Continuing Operations (in dollars per share) | 3.91 | 3.94 | 2.49 |
| Discontinued Operations (in dollars per share) | 0 | 0 | 0.01 |
| Net Earnings (in dollars per share) | $ 3.91 | $ 3.94 | $ 2.50 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,753 | 1,775 | 1,773 |
| Dilutive Common Stock Options (in shares) | 11 | 14 | 13 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) | 1,764 | 1,789 | 1,786 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 3 | 0 | 9 |
ABT Balance Sheet
2022-12-31Consolidated Balance Sheet - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 9,882 | $ 9,799 |
| Investments, primarily bank time deposits and U.S. treasury bills | 288 | 450 |
| Trade receivables, less allowances of — 2022: $500; 2021: $519 | 6,218 | 6,487 |
| Inventories: | ||
| Finished products | 3,805 | 3,081 |
| Work in process | 680 | 694 |
| Materials | 1,688 | 1,382 |
| Total inventories | 6,173 | 5,157 |
| Other prepaid expenses and receivables | 2,663 | 2,346 |
| Total current assets | 25,224 | 24,239 |
| Investments | 766 | 816 |
| Property and equipment, at cost: | ||
| Land | 511 | 525 |
| Buildings | 4,053 | 4,007 |
| Equipment | 14,164 | 13,528 |
| Construction in progress | 1,484 | 1,304 |
| Property and equipment, at cost | 20,212 | 19,364 |
| Less: accumulated depreciation and amortization | 11,050 | 10,405 |
| Net property and equipment | 9,162 | 8,959 |
| Intangible assets, net of amortization | 10,454 | 12,739 |
| Goodwill | 22,799 | 23,231 |
| Deferred income taxes and other assets | 6,033 | 5,212 |
| Total Assets | 74,438 | 75,196 |
| Current liabilities: | ||
| Trade accounts payable | 4,607 | 4,408 |
| Salaries, wages and commissions | 1,556 | 1,625 |
| Other accrued liabilities | 5,845 | 5,181 |
| Dividends payable | 887 | 831 |
| Income taxes payable | 343 | 306 |
| Current portion of long-term debt | 2,251 | 754 |
| Total current liabilities | 15,489 | 13,105 |
| Long-term debt | 14,522 | 17,296 |
| Post-employment obligations and other long-term liabilities | 7,522 | 8,771 |
| Commitments and contingencies | ||
| Shareholders’ investment: | ||
| Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued | 0 | 0 |
| Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2022: 1,986,519,278; 2021: 1,985,273,421 | 24,709 | 24,470 |
| Common shares held in treasury, at cost — Shares: 2022: 248,724,257; 2021: 221,191,228 | (15,229) | (11,822) |
| Earnings employed in the business | 35,257 | 31,528 |
| Accumulated other comprehensive income (loss) | (8,051) | (8,374) |
| Total Abbott Shareholders’ Investment | 36,686 | 35,802 |
| Noncontrolling interests in subsidiaries | 219 | 222 |
| Total Shareholders’ Investment | 36,905 | 36,024 |
| Total Liabilities and Shareholders' Investment | $ 74,438 | $ 75,196 |